awesome results!
I went for my 12 week eot draw last week and my study coordinator (my angel) told me she would be receiving a letter in two weeks & while not very specific I assume it would the 12 week SVR letter. She said she would call when she got it.
My most recent blood work was very promising on an overall level
liver enzymes were at12 yr record lows for me low end of normal
Hemo back up over 16
white blood cells in normal range another record for me
I have been experiencing some neuropathy in my in my feet but since I think we are all a little gun shy I am really not sure if its a side effect or unrelated. I had been running on the beach which I have curtailed for now & plan to seek alternative cardio & see a doc for diagnosis
all in all I feel great - lot of energy and renewed confidence.
went a bought a new to me race car for Christmas - 1970 911s, renewed my licenses to race in historics (where I belong at my age) and am planning my season..
who would have thunk it at 61?
thanks for opening the link I posted;-)
happy new year to you too.
http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients?mode=print
(per the link provided by Geshmit)
"Of the 1,518 patients randomized to the 12-week arms of ION-1 and to all arms of ION-2 and ION-3, 1,456 patients (95.9 percent) achieved the primary efficacy endpoint of SVR12. Of the 62 patients (4.1 percent) who failed to achieve SVR12, 36 patients (2.4 percent) experienced virologic failure: 35 due to relapse and only one patient due to on-treatment breakthrough (with documented non-compliance). Twenty-six patients (1.7 percent) were lost to follow-up or withdrew consent.
Fewer adverse events were observed in the RBV-free, fixed-dose combination arms compared to the RBV-containing arms in all ION studies. Adverse events observed in those taking the SOF/LDV tablet were generally mild and included fatigue and headache. In the RBV-containing arms of the ION studies, the most common adverse events were fatigue, headache, nausea and insomnia. Anemia, which is a common side effect associated with RBV, was reported in 0.5 percent of patients in the SOF/LDV arms versus 9.2 percent of patients in the RBV-containing arms. Less than 1 percent of patients in the studies discontinued treatment due to treatment-emergent adverse events."
================
If you check out natap they usually have great presentations with nice graphics.
For instance check this out. AE chart at bottom of the "page";
http://www.natap.org/2013/hepDART/hepDART_10.htm
====================
please also note.......I have yet to see AE results ever list tinnitus or neuropathy. Perhaps they are not...."adverse" enough, ,,,,,,,,,,,,,,,,,,,,,,,,but nerve damage/tinnitus is quite often serious and permanent, whereas drug induced forms of anemia are almost always transitory.......
I do not understand, but it seems to be something that I witness.
happy new year....
willy
Another reason to be grateful.
The cost of the drugs we've been given for free is likely to be prohibitive...
http://vaccinenewsdaily.com/medical_countermeasures/329106-new-hcv-drug-could-cost-1000-per-pill/
Hi again
Try this link from Gilead's website - it mentions sides. Gilead is publishing its results on its site, so good to take a look there
http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients?mode=print
I will have to look for a link. I have the trial results in hard copy that someone printed out for me from a medical publication - I couldn't access the full version online But will have a look. Perhaps Willy50's link has it?